Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new
drug approvals and a massive pipeline of additional treatments in clinical and preclinical …

Objective To review published cases of induced or exacerbated interstitial lung disease
(ILD) in rheumatoid arthritis (RA) associated with non-biologic disease-modifying …

Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung
disease (ILD)(RA-ILD). Methods This was an observational, multicentre study of RA-ILD …

Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased
the frequency and broadened the spectrum of lung toxicity, particularly in patients with …

A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a
regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been …

Objective Interstitial lung disease (ILD) is one of the most serious complications of
rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept …

Interstitial lung disease (ILD) accounts for the major cause of morbidity and mortality in
rheumatoid arthritis (RA). However, little is known of the pathogenesis, diagnosis and …

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary …

Introduction: Biological drugs are therapies designed to target a specific molecule of the
immune system that have been linked with the development of autoimmune diseases. Areas …

Fifteen monoclonal antibodies (mAbs) are currently registered and approved for the
treatment of a range of different cancers. These mAbs are specific for a limited number of …